Ginsenoside Rg2|52286-74-5|(人参皂苷 Rg2; Chikusetsusaponin I; Panaxoside Rg2; Prosapogenin C2)-陌孚医药/Medlife

您当前的位置：

Ginsenoside Rg2 (Synonyms: 人参皂苷 Rg2; Chikusetsusaponin I; Panaxoside Rg2; Prosapogenin C2)

目录号: PC13410 纯度: ≥98%

CAS No. :52286-74-5

商品编号	规格	价格	会员价	是否有货	数量
PC13410-20mg	20mg	¥1911.00	请登录

Medlife所售产品仅用于科学研究（非临床研究），非药品不可食用，不可用于人体或动物的临床诊断和治疗，我们不为个人提供产品及服务。产品COA等资料，可至下方“质量控制”中下载。

加入购物车在线咨询收藏产品大包装询价

中文名称

Ginsenoside Rg2

中文别名

人参皂苷 Rg2;人参皂荚RG2;(R型)人参皂苷;人参皂苷-RG2;人参皂苷RG2(S);(R型)人参皂苷RG2;(S型)人参皂苷RG2;人参皂苷RG2(标准品);人参皂苷20(S)-RG2;S-人参皂苷RG2,人参皂甙RG2;1-N-叔丁氧羰基-3-氧代哌啶-4-甲酸乙酯;20(S)-人参皂苷Rg2;人参皂甙 Rg2;人参皂苷 Rg2 Ginsenoside Rg2;人参皂苷 Rg2 原薯蓣皂苷蛇床子素麝香酮;人参皂苷Rg2 对照品标准品;人参皂苷Rg2 标准品;人参皂苷Rg2,Ginsenoside-Rg2,植物提取物,标准品,对照品;分析对照品;人参皂苷Rg2(20(S)-人参皂苷Rg2,人参皂甙Rg2)

英文名称

Ginsenoside Rg2

英文别名

Ginsenoside Rg2;anaxatriol;GinsesideRg2;PROSAPOGENIN C2;iGInsenoside Rg2;CHIKUSETSUSAPONIN I;GINSENOSIDE Rg2(SH);Ginsenoside 20(s)-Rg2;20(S)-Ginsenoside Rg2;CHIKUSETSUSAPONIN I,PROSAPOGENIN C2;GINSENOSIDE Rg2 (S-FORM)(AS) PrintBack;Ginsenoside-Rg2;Panaxoside Rg2;(3β,6α,12β)-3,12,20-Trihydroxydammar-24-en-6-yl 2-O-(6-deoxy-α-L-mannopyranosyl)-β-D-glucopyranoside;Dammarane,b-D-glucopyranoside deriv.;GF VI;PanaxosideRg2;20(S)-Ginsenoside-Rg2;(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,6S,8R,9R,10R,12R,13R,17S)-3,12-Dihydroxy-17-[(2S)-2-hyd;A829011;(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-2-[[(3S,6S,8R,9R,10R,12R,13R,17S)-3,12-dihydroxy-17-[(2S)-2-hyd

Cas No.

52286-74-5

分子式

C₄₂H₇₂O₁₃

分子量

785.01

包装储存

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

生物活性

Ginsenoside Rg2 is one of the major active components of ginseng. Ginsenoside Rg2 inhibits VCAM-1 and ICAM-1 expressions stimulated with lipopolysaccharide (LPS). Ginsenoside Rg2 also reduces Aβ_1-42 accumulation.

性状

Solid

IC50 & Target[1][2]

NF-κB

Aβ_1-42

体外研究(In Vitro)

Ginsenoside Rg2 prevents the decrease of IκB expression stimulated with lipopolysaccharide (LPS). IκB dissociation from RelA-p50 complex is crucial for NF-κB activity. Ginsenoside Rg2, protopanaxatriol, inhibits vascular cell adhesion molecule 1 (VCAM-1) and intercellular adhesion molecule 1 (ICAM-1) expression stimulated with LPS from human umbilical vein endothelial cell (HUVEC). The inhibition of VCAM-1 and ICAM-1 expression by Ginsenoside Rg2 is in a concentration-dependent manner, significantly. Treatment of endothelial cells with LPS (1μg/mL) decreases IκBα expression. By 1 hr after LPS treatment, significant decrease of IκBα is attained. To determine whether LPS-stimulated IκBα expression is affected by Ginsenoside Rg2, endothelial cells are treated for 1 hr with Ginsenoside Rg2 (1~50 μM) prior to LPS (1 μg/mL) stimulation for 1 hr. Ginsenoside Rg2 reverses the decrease of LPS-induced IκBα expression in a concentration-dependent manner, significantly. The adhesion of THP-1 cells to endothelial cells is measured using quantitative monolayer adhesion assay. The adhesion of THP-1 cells onto endothelial cells are increased to five folds by LPS (1 μg/mL) stimulation for 8 hrs. Ginsenoside Rg2 (1~50 μM) inhibits the adhesion of THP-1 cells to endothelial cells stimulated with LPS, in a concentration-dependent manner.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究(In Vivo)

G-Rg1 and Ginsenoside Rg2 (G-Rg2) reduce the escape latencies on the last two training days compared to the Alzheimers disease (AD) model group (p<0.05). In the spatial exploration test, the total time spent in the target quadrant and the number of mice that exactly crossed the previous position of the platform are clearly shorter and lower, respectively, in the AD model group mice than in the normal control group mice (p<0.01), a trend that is reversed by treatment with G-Rg1 and Ginsenoside Rg2 (G-Rg1, p<0.01; Ginsenoside Rg2, p<0.05). Treatment with G-Rg1 and Ginsenoside Rg2 effectively improve cognitive function of the mice that have declined due to AD. G-Rg1 and Ginsenoside Rg2 reduce Aβ_1-42 accumulation in APP/PS1 mice. In the G-Rg1 and Ginsenoside Rg2 treated mice, the pathological abnormalities observed in the APP/PS1 mice are gradually ameliorated. Clear nucleoli and light brown, sparsely scattered Aβ deposits are visible.

Medlife has not independently confirmed the accuracy of these methods. They are for reference only.

运输条件

Room temperature or refrigerated transportation.

储存方式

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

结构分类

来源

参考文献

[1]. Cho YS, et al. Ginsenoside rg2 inhibits lipopolysaccharide-induced adhesion molecule expression in human umbilical vein endothelial cell. Korean J Physiol Pharmacol. 2013 Apr;17(2):133-7. [Information]

[2]. Li N, et al. A UPLC/MS-based metabolomics investigation of the protective effect of ginsenosides Rg1 and Rg2 in mice with Alzheimers disease. J Ginseng Res. 2016 Jan;40(1):9-17. [Information]

[3]. Cho YS, et al. Ginsenoside rg2 inhibits lipopolysaccharide-induced adhesion molecule expression in human umbilical vein endothelial cell. Korean J Physiol Pharmacol. 2013;17(2):133-137. [Information]

溶解度数据

体外研究:

DMSO : 50 mg/mL (63.69 mM; Need ultrasonic)

配制储备溶液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	1.2739 mL	6.3693 mL	12.7387 mL
5 mM	0.2548 mL	1.2739 mL	2.5477 mL
10 mM	0.1274 mL	0.6369 mL	1.2739 mL

产品不同，其溶解度不同。建议根据产品选择合适的溶剂配制储备溶液；配成溶液后，建议分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，建议在 6 个月内使用，-20°C 储存时，建议在 1 个月内使用。

体内研究:

建议根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都建议先按照 体外研究 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

建议依照次序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.18 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH?O 中，得到澄清透明的生理盐水溶液
2.

建议依照次序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.18 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

建议依照次序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.5 mg/mL (3.18 mM); Clear solution

此方案可获得 ≥ 2.5 mg/mL (3.18 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 25.0 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。

搜索质检报告(COA)

产品使用指南

Data Sheet

1：一般建议：溶解度为Medlife测试数据，可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异，仅做参考，具体以实验方案为准。

2：储存条件：粉末-20°C一般情况可以保存3年，溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异，请细致阅读产品信息，并辅助参考相关文献描述。

相关产品

The molarity calculator equation

The dilution calculator equation